Literature DB >> 7448340

Disposition kinetics of disopyramide in patients with renal insufficiency.

D D Shen, J L Cunningham, I Shudo, D L Azarnoff.   

Abstract

The pharmacokinetics of an intravenous injection of disopyramide was studied in five normal subjects and six patients with varying degrees of renal impairment. The elimination rate constant (beta) was related to the endogenous creatinine clearance (Clcr). However, a decrease in beta was not observed until the Clcr was reduced below 40 ml min-1. Below 40 ml min-1 a linear relationship existed between beta and Clcr. Similarly, the plasma elimination half-life (t 1/2 beta) showed a significant increase when the Clcr was less than 30 ml min-1. Hence, dosage modification for disopyramide is necessary only when renal function is severely impaired. Overall, the apparent volume of distribution in patients with renal insufficiency was reduced to two-thirds of that in normal subjects. Therefore, in patients with Clcr less than 40 ml min-1 both the loading and maintenance dose of disopyramide should be reduced.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7448340     DOI: 10.1002/bdd.2510010308

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  10 in total

Review 1.  Is antiarrhythmic treatment in the elderly different? a review of the specific changes.

Authors:  Vera H M Deneer; Norbert M van Hemel
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

4.  Pharmacokinetics of disopyramide in patients with chronic renal failure.

Authors:  B Francois; R Mallein; J Rondelet; M Lussignol
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

5.  OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.

Authors:  A W Kelman; B Whiting; S M Bryson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 6.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

7.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.

Authors:  H L Elliott; A H Thomson; S M Bryson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

Review 10.  Reliability of antiarrhythmic drug plasma concentration monitoring.

Authors:  F Follath; U Ganzinger; E Schuetz
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.